JP2010502614A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010502614A5 JP2010502614A5 JP2009526683A JP2009526683A JP2010502614A5 JP 2010502614 A5 JP2010502614 A5 JP 2010502614A5 JP 2009526683 A JP2009526683 A JP 2009526683A JP 2009526683 A JP2009526683 A JP 2009526683A JP 2010502614 A5 JP2010502614 A5 JP 2010502614A5
- Authority
- JP
- Japan
- Prior art keywords
- benzodiazepine
- composition
- solvent
- mammal
- transmucosal administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229940049706 benzodiazepine Drugs 0.000 claims description 61
- 239000000203 mixture Substances 0.000 claims description 53
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 51
- 239000002904 solvent Substances 0.000 claims description 36
- 241000124008 Mammalia Species 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
- 150000001557 benzodiazepines Chemical class 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- 208000019901 Anxiety disease Diseases 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 150000005215 alkyl ethers Chemical class 0.000 claims description 6
- 229960003529 diazepam Drugs 0.000 claims description 6
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 6
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical group CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 6
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 210000004400 mucous membrane Anatomy 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims description 4
- 229960003120 clonazepam Drugs 0.000 claims description 4
- 229960004391 lorazepam Drugs 0.000 claims description 4
- 238000011287 therapeutic dose Methods 0.000 claims description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical group CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 4
- 239000012062 aqueous buffer Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 claims description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical group CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 2
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 claims description 2
- 206010033664 Panic attack Diseases 0.000 claims description 2
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 claims description 2
- 206010071350 Seizure cluster Diseases 0.000 claims description 2
- 206010041250 Social phobia Diseases 0.000 claims description 2
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 claims description 2
- 229960004538 alprazolam Drugs 0.000 claims description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims description 2
- 229940035674 anesthetics Drugs 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 229960002729 bromazepam Drugs 0.000 claims description 2
- 229960004782 chlordiazepoxide Drugs 0.000 claims description 2
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 claims description 2
- 229960001403 clobazam Drugs 0.000 claims description 2
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 claims description 2
- 229960004362 clorazepate Drugs 0.000 claims description 2
- XDDJGVMJFWAHJX-UHFFFAOYSA-N clorazepic acid Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)O)N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-N 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000006184 cosolvent Substances 0.000 claims description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 229960002336 estazolam Drugs 0.000 claims description 2
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 229960002200 flunitrazepam Drugs 0.000 claims description 2
- 229960003528 flurazepam Drugs 0.000 claims description 2
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 239000003193 general anesthetic agent Substances 0.000 claims description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 2
- 229960002158 halazepam Drugs 0.000 claims description 2
- 239000012456 homogeneous solution Substances 0.000 claims description 2
- 229960004423 ketazolam Drugs 0.000 claims description 2
- PWAJCNITSBZRBL-UHFFFAOYSA-N ketazolam Chemical compound O1C(C)=CC(=O)N2CC(=O)N(C)C3=CC=C(Cl)C=C3C21C1=CC=CC=C1 PWAJCNITSBZRBL-UHFFFAOYSA-N 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 229960003019 loprazolam Drugs 0.000 claims description 2
- UTEFBSAVJNEPTR-RGEXLXHISA-N loprazolam Chemical compound C1CN(C)CCN1\C=C/1C(=O)N2C3=CC=C([N+]([O-])=O)C=C3C(C=3C(=CC=CC=3)Cl)=NCC2=N\1 UTEFBSAVJNEPTR-RGEXLXHISA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 210000002850 nasal mucosa Anatomy 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 208000019906 panic disease Diseases 0.000 claims description 2
- 230000000149 penetrating effect Effects 0.000 claims description 2
- 230000035515 penetration Effects 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 claims description 2
- 229960005214 tetrazepam Drugs 0.000 claims description 2
- IQWYAQCHYZHJOS-UHFFFAOYSA-N tetrazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CCCCC1 IQWYAQCHYZHJOS-UHFFFAOYSA-N 0.000 claims description 2
- 229960002622 triacetin Drugs 0.000 claims description 2
- 229960003386 triazolam Drugs 0.000 claims description 2
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84056806P | 2006-08-28 | 2006-08-28 | |
| PCT/US2007/018942 WO2008027395A2 (en) | 2006-08-28 | 2007-08-27 | Pharmaceutical compositions of benzodiazepines and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010502614A JP2010502614A (ja) | 2010-01-28 |
| JP2010502614A5 true JP2010502614A5 (https=) | 2011-08-25 |
Family
ID=38819711
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009526675A Ceased JP2010502612A (ja) | 2006-08-28 | 2007-08-27 | クロナゼパムの薬学的組成物およびその使用方法 |
| JP2009526683A Ceased JP2010502614A (ja) | 2006-08-28 | 2007-08-27 | ベンゾジアゼピンの薬学的組成物およびその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009526675A Ceased JP2010502612A (ja) | 2006-08-28 | 2007-08-27 | クロナゼパムの薬学的組成物およびその使用方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8716279B2 (https=) |
| EP (2) | EP2068933A2 (https=) |
| JP (2) | JP2010502612A (https=) |
| KR (1) | KR20090043603A (https=) |
| CN (1) | CN101528261B (https=) |
| AR (1) | AR062556A1 (https=) |
| AU (1) | AU2007290589B2 (https=) |
| BR (1) | BRPI0714907A2 (https=) |
| CA (1) | CA2662197A1 (https=) |
| IL (1) | IL197275A0 (https=) |
| MX (1) | MX2009002310A (https=) |
| NO (1) | NO20091211L (https=) |
| NZ (2) | NZ575744A (https=) |
| PE (1) | PE20081361A1 (https=) |
| TW (1) | TW200824693A (https=) |
| UY (1) | UY30561A1 (https=) |
| WO (2) | WO2008027357A2 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200824693A (en) * | 2006-08-28 | 2008-06-16 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of clonazepam and methods of use thereof |
| CN101678112B (zh) * | 2007-01-19 | 2016-08-31 | 哈南亚有限公司 | 用于递送治疗剂的方法和组合物 |
| US20080275030A1 (en) | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
| NZ583265A (en) | 2007-08-31 | 2012-01-12 | Archimedes Dev Ltd | Pharmaceutical compositions comprising a benzodiazepine drug and a non-aqueous vehicle comprising propylene glycol and propylene carbonate |
| GB0716907D0 (en) * | 2007-08-31 | 2007-10-10 | Archimedes Dev Ltd | Pharmaceutical powder compositions |
| CA2756690C (en) | 2008-03-28 | 2016-08-16 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine compositions |
| KR101517415B1 (ko) * | 2008-05-14 | 2015-05-07 | 에스케이바이오팜 주식회사 | 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물 |
| WO2010126970A1 (en) * | 2009-04-28 | 2010-11-04 | Optmed, Inc. | Methods for treating and preventing erectile dysfunction |
| CA2760451A1 (en) * | 2009-04-28 | 2010-11-04 | Optmed, Inc. | Compositions and methods for treating and preventing overactive bladder and conditions associated therewith |
| GB2481407B (en) * | 2010-06-22 | 2012-05-23 | Special Products Ltd | A rapid onset liquid midazolam composition for buccal administration |
| PH12013501915A1 (en) * | 2011-03-31 | 2019-11-29 | Acorda Therapeutics Inc | Intranasal benzodiazepine pharmaceutical compositions |
| EP4085899A1 (en) | 2011-06-14 | 2022-11-09 | Neurelis, Inc. | Administration of benzodiazepine |
| AU2012352528B9 (en) * | 2011-12-11 | 2017-11-02 | Baudax Bio, Inc. | Intranasal dexmedetomidine compositions and methods of use thereof |
| US9125805B2 (en) * | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
| US8999393B1 (en) * | 2013-01-09 | 2015-04-07 | Edgemont Pharmaceuticals Llc | Sustained release formulations of lorazepam |
| WO2014127459A1 (en) * | 2013-02-22 | 2014-08-28 | Eastgate Pharmaceuticals Inc. | Pharmaceutical composition for enhanced transmucosal administration of benzodiazepines |
| KR101635635B1 (ko) * | 2014-12-04 | 2016-07-01 | 주식회사 엘지생활건강 | 디팔미토일 하이드록시프롤린과 갈릭산 에스터 유도체를 함유하는 화장료 조성물 |
| US20180104366A1 (en) | 2015-05-25 | 2018-04-19 | Isotherapeutics Group, Llc | Dotmp kit formulations for radioisotopes |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11241383B2 (en) * | 2016-12-09 | 2022-02-08 | Alexza Pharmaceuticals, Inc. | Method of treating epilepsy |
| WO2019099995A1 (en) * | 2017-11-17 | 2019-05-23 | Neurana Pharmaceuticals, Inc. | Methods of administering tolperisone |
| US11278492B2 (en) | 2018-01-05 | 2022-03-22 | Impel Neuropharma, Inc. | Intranasal delivery of olanzapine by precision olfactory device |
| US10896106B2 (en) | 2018-05-10 | 2021-01-19 | Teradyne, Inc. | Bus synchronization system that aggregates status |
| CN113473980A (zh) | 2019-03-01 | 2021-10-01 | 弗拉梅尔爱尔兰有限公司 | 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物 |
| US20200338090A1 (en) * | 2019-04-29 | 2020-10-29 | Marsh and Wang Medical Systems, LLC | Seizure control compositions and methods of using same |
| CN110420190B (zh) * | 2019-08-29 | 2021-07-09 | 湖南洞庭药业股份有限公司 | 氯硝西泮片及其制备方法 |
| CN117580579A (zh) * | 2021-06-10 | 2024-02-20 | 纽瑞莱斯有限公司 | 用于治疗儿科患者的癫痫发作病症的方法和组合物 |
| CN115707451A (zh) * | 2021-08-19 | 2023-02-21 | 北京万全德众医药生物技术有限公司 | 氯硝西泮口服溶液 |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| CN118812444A (zh) * | 2022-03-02 | 2024-10-22 | 济南同路医药科技发展有限公司 | 一种喹唑啉类化合物及其制备方法和应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5266466A (en) * | 1987-01-14 | 1993-11-30 | President And Fellows Of Harvard College | Method of using T7 DNA polymerase to label the 3' end of a DNA molecule |
| SE8800080L (sv) | 1988-01-13 | 1989-07-14 | Kabivitrum Ab | Laekemedelskomposition |
| US4950664A (en) * | 1988-09-16 | 1990-08-21 | Rugby-Darby Group Companies, Inc. | Nasal administration of benzodiazepine hypnotics |
| FR2656303B1 (fr) * | 1989-12-26 | 1994-06-10 | Parke Davis | Solution buvable d'un derive des benzodiazepines et son application pharmacologique. |
| ES2117642T3 (es) * | 1990-05-10 | 1998-08-16 | Bechgaard Int Res | Preparado farmaceutico que contiene n-glicofuroles y n-etilen glicoles. |
| DE4021263C2 (de) * | 1990-07-04 | 1996-04-11 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung für Medien |
| FR2692174B1 (fr) * | 1992-06-16 | 1994-08-19 | Valois | Dispositif à gaz comprimé pour projeter sous forme finement divisée une dose unique d'une substance fluide. |
| DK17093D0 (da) | 1993-02-15 | 1993-02-15 | Lyfjathroun H F | Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder |
| WO1995029678A1 (en) | 1994-04-28 | 1995-11-09 | F.Hoffmann-La Roche Ag | Pharmaceutical composition for transdermal delivery |
| GB9409778D0 (en) * | 1994-05-16 | 1994-07-06 | Dumex Ltd As | Compositions |
| US20050163719A1 (en) * | 1997-10-01 | 2005-07-28 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing diazepam |
| DE19756442A1 (de) | 1997-12-18 | 1999-06-24 | Pfeiffer Erich Gmbh & Co Kg | Spender für Medien |
| US6699849B1 (en) * | 1998-02-23 | 2004-03-02 | Cyclops, Ehf. | Cyclodextrin complexes of benzodiazepines |
| SE9803240D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | A pharmaceutical composition having a rapid action |
| GB9826192D0 (en) * | 1998-12-01 | 1999-01-20 | Controlled Theraputics Scotlan | Oral transmucosal delivery |
| MXPA02001612A (es) * | 1999-07-26 | 2003-10-14 | Sk Corp | Composiciones anti-convulsivas transnasales y procedimiento modular. |
| DE19938798A1 (de) | 1999-08-16 | 2001-03-01 | Pfeiffer Erich Gmbh & Co Kg | Spender für Flüssigkeiten oder für zähflüssige oder versprühbare Produkte |
| DE19940236A1 (de) * | 1999-08-25 | 2001-03-08 | Pfeiffer Erich Gmbh & Co Kg | Spender mit manuell betätigbarer Ausbringeinrichtung |
| US6610271B2 (en) | 2000-05-10 | 2003-08-26 | University Of Kentucky Research Foundation | System and method for intranasal administration of lorazepam |
| ATE355854T1 (de) | 2000-08-03 | 2007-03-15 | Antares Pharma Ipl Ag | Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel |
| FR2815611B1 (fr) * | 2000-10-23 | 2003-04-11 | Valois Sa | Tete de distribution et distributeur de produit fluide comportant une telle tete de distribution |
| US20040176359A1 (en) * | 2001-02-20 | 2004-09-09 | University Of Kentucky Research Foundation | Intranasal Benzodiazepine compositions |
| US7262185B2 (en) * | 2001-08-08 | 2007-08-28 | Takeda Chemical Industries Ltd. | Benzazepine derivative, process for producing the same, and use |
| BR0307913A (pt) | 2002-02-25 | 2005-01-11 | Lyfjathroun Hf | Uso de uma composição, composição farmacêutica para administração nasal, e, métodos para eliciar um efeito terapêutico, profilático e/ou diagnóstico em um mamìfero, para obter um inìcio rápido de um efeito terapêutico, profilático e/ou diagnóstico de uma substância ativa em um mamìfero e para melhorar a biodisponibilidade de um efeito terapêutico, profilático e/ou diagnóstico de uma substância ativa em um mamìfero |
| US6742677B2 (en) | 2002-04-18 | 2004-06-01 | Valois S.A.S. | Fluid dispenser pump |
| JP2005531570A (ja) * | 2002-05-23 | 2005-10-20 | ユーエムディー， インコーポレイテッド | 貫粘膜薬物送達及び凍結保護のための組成物及び方法 |
| US6855332B2 (en) | 2002-07-03 | 2005-02-15 | Lyfjathroun Hf. | Absorption promoting agent |
| ITRM20020357A1 (it) * | 2002-07-03 | 2004-01-05 | Foscama Biomed Chim Farma | Composizione liquida per la somministrazione orale di lorazepam. |
| JP2006516616A (ja) | 2003-01-31 | 2006-07-06 | オレクソ・アクチエボラゲット | 即効薬剤組成物 |
| JP2006527764A (ja) * | 2003-06-17 | 2006-12-07 | エスケー コーポレイション | ジアゼパムを含有する経鼻マイクロエマルジョン |
| DK1670433T3 (da) * | 2003-10-10 | 2012-03-12 | Ferring Bv | Transdermal farmaceutisk formulering til mindskelse af hudrester |
| JP5144277B2 (ja) | 2005-01-14 | 2013-02-13 | カムルス エービー | 局所用生体付着性製剤 |
| US20070021411A1 (en) | 2005-05-11 | 2007-01-25 | Cloyd James C | Supersaturated benzodiazepine solutions and their delivery |
| TW200824693A (en) | 2006-08-28 | 2008-06-16 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of clonazepam and methods of use thereof |
| US9319244B2 (en) | 2010-12-22 | 2016-04-19 | Usablenet Inc. | Methods for emailing labels as portable data files and devices thereof |
-
2007
- 2007-08-14 TW TW096130010A patent/TW200824693A/zh unknown
- 2007-08-23 PE PE2007001144A patent/PE20081361A1/es not_active Application Discontinuation
- 2007-08-27 BR BRPI0714907-7A patent/BRPI0714907A2/pt not_active IP Right Cessation
- 2007-08-27 WO PCT/US2007/018877 patent/WO2008027357A2/en not_active Ceased
- 2007-08-27 US US11/897,002 patent/US8716279B2/en not_active Expired - Fee Related
- 2007-08-27 NZ NZ575744A patent/NZ575744A/en not_active IP Right Cessation
- 2007-08-27 US US11/897,028 patent/US8609651B2/en not_active Expired - Fee Related
- 2007-08-27 EP EP07837400A patent/EP2068933A2/en not_active Withdrawn
- 2007-08-27 KR KR1020097006303A patent/KR20090043603A/ko not_active Ceased
- 2007-08-27 CA CA002662197A patent/CA2662197A1/en not_active Abandoned
- 2007-08-27 JP JP2009526675A patent/JP2010502612A/ja not_active Ceased
- 2007-08-27 MX MX2009002310A patent/MX2009002310A/es not_active Application Discontinuation
- 2007-08-27 CN CN2007800399467A patent/CN101528261B/zh not_active Expired - Fee Related
- 2007-08-27 JP JP2009526683A patent/JP2010502614A/ja not_active Ceased
- 2007-08-27 AU AU2007290589A patent/AU2007290589B2/en not_active Ceased
- 2007-08-27 NZ NZ595388A patent/NZ595388A/en not_active IP Right Cessation
- 2007-08-27 EP EP07811570A patent/EP2056877A2/en not_active Withdrawn
- 2007-08-27 UY UY30561A patent/UY30561A1/es unknown
- 2007-08-27 WO PCT/US2007/018942 patent/WO2008027395A2/en not_active Ceased
- 2007-08-28 AR ARP070103802A patent/AR062556A1/es not_active Application Discontinuation
-
2009
- 2009-02-26 IL IL197275A patent/IL197275A0/en unknown
- 2009-03-23 NO NO20091211A patent/NO20091211L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010502614A5 (https=) | ||
| JP2010502612A5 (https=) | ||
| US10758479B2 (en) | Galenical form for the administration of active ingredients by transmucous means | |
| CN100522245C (zh) | 用于穿粘膜的药物输送和冷冻保护的组合物 | |
| JP5832451B2 (ja) | 抗真菌医薬組成物 | |
| JP2020037557A (ja) | 医薬水中油型ナノエマルジョン | |
| US20110263606A1 (en) | Solid oral dosage forms comprising tadalafil | |
| JP5877939B2 (ja) | 治療薬を送達するための方法および組成物 | |
| CA2543324A1 (en) | Rapidly disintegrating films for delivery of pharmaceutical or cosmetic agents | |
| TW200922635A (en) | Non-aqueous pharmaceutical compositions | |
| CN101384249A (zh) | 可崩解口腔膜剂 | |
| JPH05507085A (ja) | ｎ―グリコフロール類及びｎ―エチレングリコール類を含有する医薬製剤 | |
| KR20130060179A (ko) | 동결건조된 속용, 다상 제형의 제조 방법 | |
| JP2010526837A (ja) | 抗不眠症組成物および方法 | |
| JP2017155060A5 (https=) | ||
| CN100594936C (zh) | 改善透粘膜给药制剂的吸收的方法 | |
| JP2001521502A (ja) | Ｃ型肝炎の治療へのアマンタジンの使用 | |
| WO2020030991A1 (en) | Dosage form for insertion into the mouth | |
| JP2022173567A (ja) | 注腸剤 | |
| JP2012505236A (ja) | コルチコステロイド組成物およびそれの治療方法 | |
| JP2019531308A5 (https=) | ||
| CN103347518A (zh) | 含有抗毒蕈碱药物的无推进剂液体制剂 | |
| CN120265283A (zh) | (-)-表没食子儿茶素没食子酸酯类化合物的应用 | |
| JPH10298107A (ja) | 医薬組成物 | |
| CN101897720B (zh) | 一种治疗呼吸道疾病的药物组合物 |